“It was a milestone in the coronavirus pandemic, 18 long months after adults first began to receive shots against the virus. But the response was notably muted from parents, with little indication of the excitement and long lines that greeted earlier vaccine rollouts. An April poll showed that less than a fifth of parents of children under 5 were eager to access the shot right away. Early adopters in this age group appeared to be outliers.”
https://www.nytimes.com/2022/06/21/us/children-covid-vaccine.html
“While Israel has seen rising infection numbers for a few weeks, a rise in seriously ill patients marks a real concern as the country deals with the spread of the new variant BA.5, with experts warning that hospitals may need to reopen COVID wards. The number was up from 85 seriously ill patients on Friday last week.”
“A pair of new subvariants of the dominant Omicron variant—BA.4 and BA.5—appear to be driving the uptick in cases in the U.K. Worryingly, these subvariants seem to partially dodge antibodies from past infection or vaccination, making them more transmissible than other forms of the SARS-CoV-2 virus.”
https://sports.yahoo.com/news/may-covid-variant-scientists-dreading-072005463.html
“Seriousness provides information on the suspected undesirable effect; it can be classified as ‘serious’ if it corresponds to a medical occurrence that results in death, is life-threatening, requires inpatient hospitalisation, results in another medically important condition, or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a congenital anomaly/birth defect.”
“The latest sub-variants of Omicron may have evolved to target the lung, prompting fears the next wave of the Covidcould be starting.”
https://www.independent.co.uk/news/health/covid-cough-uk-cases-omicron-sub-variant-b2107411.html
“Crawford has uncovered what seems to be a smoking gun that someone altered the 2016-2019 data of the DMED database to hide an explosion of ill-defined health problems in 2021.”
“In this large sample of 1567 interventions studied within Cochrane reviews, effects of most interventions (94%) interventions were not supported by high quality evidence.”
https://www.sciencedirect.com/science/article/abs/pii/S0895435622001007#!
https://onlinelibrary.wiley.com/doi/10.1111/andr.13209
“The excess risk of serious adverse events found in our study points to the need for formal harm-benefit analyses, particularly those that are stratified according to risk of serious COVID-19 outcomes such as hospitalization or death.”
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4125239
“These include the wearing of masks and curbs on gathering sizes. Phaahla made those proposals following the decline in hospitalizations and reported cases, according to a statement dated June 20.”
Geert Vanden Bossche received his DVM from the University of Ghent, Belgium, and his PhD degree in Virology from the University of Hohenheim, Germany. He held adjunct faculty appointments at universities in Belgium and Germany. After his career in Academia, Geert joined several vaccine companies (GSK Biologicals, Novartis Vaccines, Solvay Biologicals) to serve various roles in vaccine R&D as well as in late vaccine development.
Geert then moved on to join the Bill & Melinda Gates Foundation’s Global Health Discovery team in Seattle (USA) as Senior Program Officer; he then worked with the Global Alliance for Vaccines and Immunization (GAVI) in Geneva as Senior Ebola Program Manager. At GAVI he tracked efforts to develop an Ebola vaccine. He also represented GAVI in fora with other partners, including WHO, to review progress on the fight against Ebola and to build plans for global pandemic preparedness.
Back in 2015, Geert scrutinized and questioned the safety of the Ebola vaccine that was used in ring vaccination trials conducted by WHO in Guinea. His critical scientific analysis and report on the data published by WHO in the Lancet in 2015 was sent to all international health and regulatory authorities involved in the Ebola vaccination program. After working for GAVI, Geert joined the German Center for Infection Research in Cologne as Head of the Vaccine Development Office. He is at present primarily serving as a Biotech / Vaccine consultant while also conducting his own research on Natural Killer cell-based vaccines.
Email: info@voiceforscienceandsolidarity.org
.svg){kind=small}
